Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Deborah D. Proctor"'
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease are chronic, relapsing and remitting disorders of intestinal inflammation with potential systemic manifestations. Despite the availability of current biologics, such a
Externí odkaz:
https://doaj.org/article/b1cd60f06df94c43baf9aa2d3772b84c
Autor:
Amr Sayed, David N. Assis, Marina G. Silveira, Yanhong Deng, Maria Ciarleglio, Jill K.J. Gaidos, Deborah D. Proctor, Badr Al-Bawardy
Publikováno v:
European Journal of Gastroenterology & Hepatology. 35:270-274
Autor:
Shreyak Sharma, Darrick K Li, Louis J Levine, Abdelkader Chaar, Chandler McMillan, Jill K J Gaidos, Deborah D Proctor, Badr Al-Bawardy
Publikováno v:
Crohn's & Colitis 360.
Objectives Guidelines recommend performing a flexible sigmoidoscopy in patients hospitalized with acute severe ulcerative colitis (ASUC). However, it is unclear if time to sigmoidoscopy affects relevant clinical outcomes. We aimed to assess the impac
Autor:
Badr Al‐Bawardy, Deborah D. Proctor
Publikováno v:
Yamada's Textbook of Gastroenterology. :2293-2314
Autor:
Maria M. Ciarleglio, Jonathan T. Ohm, Ashley N. Tran, Christina Price, Loren Laine, Melinda Wang, Rishika Chugh, Alyssa Grimshaw, Badr Al-Bawardy, Melanie A. Hundt, Deborah D. Proctor, Kenneth W. Hung
Publikováno v:
Journal of Immunotherapy. 44:325-334
BACKGROUND Immune checkpoint inhibitors (ICIs) have transformed the management of advanced malignancies but are associated with diarrhea and colitis. The objective of our systematic review and meta-analysis was to determine the incidence and outcomes
Autor:
Deborah D. Proctor
Publikováno v:
Digestive Diseases and Sciences. 66:2489-2492
Autor:
Badr Al-Bawardy, Elizabeth Ruggiero, Edward V. Loftus, Christina Dimopoulos, William A. Faubion, Laurens Janssens, Deborah D. Proctor, David H. Bruining, Kenneth W. Hung, Sunanda V. Kane, Nicholas M. McDonald, Guilherme Piovezani Ramos, Laura E. Raffals
Publikováno v:
Inflammatory Bowel Diseases. 27:1270-1276
Background There are limited data on how vedolizumab (VDZ) impacts extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD). The aim of this study was to determine the clinical outcomes of EIMs after initiation of VDZ for patients wi
Publikováno v:
Digestive Diseases and Sciences. 66:181-189
Sleep disturbance is common in inflammatory bowel disease (IBD) and is associated with poorer quality of life and increased disease activity; however, sleep is a multidimensional process, and little is known about specific sleep characteristics and r
Publikováno v:
Crohn's & Colitis 360. 3
Background Despite being susceptible to vaccine-preventable diseases, patients with inflammatory bowel disease (IBD) have low vaccination rates. The aims of this study are to examine the rates of vaccine discussion and completion among patients of an
Publikováno v:
Annals of gastroenterology. 35(3)
Vedolizumab is used in inflammatory bowel disease (IBD), administered as a non-weight-based fixed dose. A higher body mass index (BMI) is associated with lower serum vedolizumab levels, but it is unclear whether it is associated with an unfavorable r